Original article

Impact of sarcopenia on quality of life and mobility in elderly patients with chronic obstructive pulmonary disease

Expand
  • Department of Geriatrics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2022-11-01

  Online published: 2024-03-18

Abstract

Objective To observe the status of sarcopenia in elderly patients with stable chronic obstructive pulmonary disease(COPD), and to explore its effect on quality of life and mobility in COPD patients. Methods A total of 92 patients with stable COPD in the Department of Geriatrics of Ruijin Hospital from July 2019 to April 2021 were selected and divided into sarcopenia group(n=32) and non-sarcopenia group(n=60) according to the Asian diagnostic criteria for sarcopenia. General clinical data were collected. All patients completed the pulmonary function test, grip strength and 6-meter walking speed measurement. The body composition analyzer was used to measure appendicular skeletal muscle (ASM), and the limb skeletal muscle mass index(SMI) was calculated. Symptoms of dyspnea were assessed by modified Medical Research Council Scal (mMRC) and the COPD assessment test (CAT). Pearson’s method or Spearman’s method was used to analyze the correlation between skeletal muscle assessment indexes and COPD disease assessment indexes. Multivariate stepwise Logistic regression was used to analyze the effect on mobility in the COPD patients with sarcopenia. Results The incidence of sarcopenia in the COPD patients was 34.8%. Compared with the non-sarcopenia group, the patients in the sarcopenia group were older (P<0.05), and the hemoglobin, albumin, body mass index (BMI), grip strength, 6-meter walking speed, ASM and SMI were significantly lower(P<0.01). CAT score and mMRC questionnaire score were higher than those in the non-sarcopenia group (P<0.05). BMI was positively correlated with first second forced end-expiratory volume as a percentage of estimated value(FEV1%)(r=0.376, P=0.031) and 6-meter walking speed(r=0.436, P=0.015) in both groups, and negatively correlated with mMRC(r=-0.340, P=0.032) and CAT (r=-0.354, P=0.043). Logistic regression analysis showed that SMI was an independent risk factor for decreased quality of life and mobility in the COPD patients after adjusting for confounding factors (P<0.05). Conclusions Sarcopenia is a common complication in elderly patients with COPD and is associated with decreased quality of life and mobility.

Cite this article

ZHAO Yajie, HE Qing, XU Zhihong . Impact of sarcopenia on quality of life and mobility in elderly patients with chronic obstructive pulmonary disease[J]. Journal of Internal Medicine Concepts & Practice, 2023 , 18(06) : 383 -387 . DOI: 10.16138/j.1673-6087.2023.06.002

References

[1] Singh D. Pharmacological treatment of stable chronic obstructive pulmonary disease[J]. Respirology, 2021, 26(7):643-651.
[2] Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis[J]. Age Ageing. 2019, 48(1):16-31.
[3] Kyomoto Y, Asai K, Yamada K, et al. Handgrip strength measurement in patients with chronic obstructive pulmonary disease[J]. Respir Investig, 2019, 57(5): 499-505.
[4] Wang X, Liang Q, Li Z, et al. Body composition and COPD[J]. Int J Chron Obstruct Pulmon Dis, 2023, 18: 79-97.
[5] Jacobsen PA, van ’t Hul AJ, Djamin RS, et al. Characteristics and treatable traits of patients with chronic obstructive pulmonary disease (COPD) with and without paid employment[J]. Respir Res, 2021, 22(1): 147.
[6] 时延伟, 张二明, 郭伟安, 等. CAT评分对慢性阻塞性肺疾病患者病情及疗效的评估价值[J]. 基层医学论坛, 2021, 25(2): 152-155.
[7] Bartziokas K, Papaporfyriou A, Hillas G, et al. Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations: strengths and concerns for future needs[J]. Postgrad Med, 2023, 135(4): 327-333.
[8] Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21(3): 300-307.
[9] Tournadre A, Vial G, Capel F, et al. Sarcopenia[J]. Joint Bone Spine, 2019, 86(3): 309-314.
[10] 胡丽, 赵旭, 黄小明. 老年慢性阻塞性肺疾病患者营养状况及其与少肌症的相关性[J]. 国际老年医学杂志, 2021, 42(1): 31-35.
[11] Trajanoska K, Schoufour JD, Darweesh SK, et al. Sarcopenia and its clinical correlates in the general population[J]. J Bone Miner Res, 2018, 33(7): 1209-1218.
[12] Sepúlveda-Loyola W, Osadnik C, Phu S, et al. Diagnosis, prevalence, and clinical impact of sarcopenia in COPD[J]. J Cachexia Sarcopenia Muscle, 2020, 11(5): 1164-1176.
[13] Benz E, Trajanoska K, Lahousse L, et al. Sarcopenia in COPD: a systematic review and meta-analysis[J]. Eur Respir Rev, 2019, 28(154): 190049.
[14] 丁怿虹, 施劲东, 刘勤, 等. 慢性阻塞性肺疾病患者体重指数和骨密度骨骼肌功能相关性研究[J]. 中国实用内科杂志, 2016, 36(8): 675-679.
[15] Chen X, Wang Q, Hu Y, et al. A Nomogram for predicting severe exacerbations in stable COPD patients[J]. Int J Chron Obstruct Pulmon Dis, 2020, 15: 379-388.
[16] Park HJ, Cho JH, Kim HJ, et al. The effect of low body mass index on the development of chronic obstructive pulmonary disease and mortality[J]. J Intern Med, 2019, 286(5): 573-582.
[17] McDonald MN, Wouters EFM, Rutten E, et al. It’s more than low BMI: prevalence of cachexia and associated mortality in COPD[J]. Respir Res, 2019, 20(1): 100.
[18] Lim JU, Lee JH, Kim JS, et al. Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients[J]. Int J Chron Obstruct Pulmon Dis, 2017, 12: 2465-2475.
[19] Guo Y, Zhang T, Wang Z, et al. Body mass index and mortality in chronic obstructive pulmonary disease[J]. Medicine (Baltimore), 2016, 95(28): e4225.
[20] 石劢, 吕春健, 赵凤梅, 等. 稳定期慢阻肺患者合并肌少症时对其生活质量的影响[J]. 中国食物营养, 2020, 26(11): 69-73.
[21] Kalu?niak-Szymanowska A, Krzymińska-Siemaszko R, Deskur-?mielecka E, et al. Malnutrition, sarcopenia, and malnutrition-sarcopenia syndrome in older adults with COPD[J]. Nutrients, 2021, 14(1): 44.
[22] Benz E, Wijnant SRA, Trajanoska K, et al. Sarcopenia, systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma[J]. ERJ Open Res. 2022, 8(1): 00628-2021.
[23] Lena A, Anker MS, Springer J. Muscle wasting and sarcopenia in heart failure-the current state of science[J]. Int J Mol Sci, 2020, 21(18): 6549.
Outlines

/